OmniAb Business Combination Approved by APAC Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Ligand Pharma (LGND) PT Lowered to $135 at H.C. Wainwright
October 25, 2022 10:47 AM EDTH.C. Wainwright analyst Joseph Pantginis lowered the price target on Ligand Pharma (NASDAQ: LGND) to $135.00 (from $310.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, Ligand announced that the combination between OmniAb and Avista Public Acquisition Corp. II (AHPA; not rated) was... More
